Presbia PLC to Post Q1 2018 Earnings of ($0.24) Per Share, Jefferies Group Forecasts (LENS)

Presbia PLC (NASDAQ:LENS) – Analysts at Jefferies Group issued their Q1 2018 earnings per share estimates for Presbia PLC in a note issued to investors on Thursday. Jefferies Group analyst R. Denhoy anticipates that the medical instruments supplier will post earnings of ($0.24) per share for the quarter. Jefferies Group currently has a “Buy” rating and a $10.00 price target on the stock. Jefferies Group also issued estimates for Presbia PLC’s Q2 2018 earnings at ($0.26) EPS, Q3 2018 earnings at ($0.35) EPS, Q4 2018 earnings at ($0.39) EPS and FY2021 earnings at ($0.45) EPS.

TRADEMARK VIOLATION NOTICE: “Presbia PLC to Post Q1 2018 Earnings of ($0.24) Per Share, Jefferies Group Forecasts (LENS)” was first posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this news story can be viewed at https://ledgergazette.com/2017/10/09/presbia-plc-to-post-q1-2018-earnings-of-0-24-per-share-jefferies-group-forecasts-lens.html.

A number of other equities research analysts have also issued reports on the stock. ValuEngine raised shares of Presbia PLC from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st. Zacks Investment Research raised shares of Presbia PLC from a “sell” rating to a “hold” rating in a report on Tuesday, July 25th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $11.33.

Shares of Presbia PLC (LENS) opened at 5.1351 on Monday. The company’s market cap is $87.07 million. The stock has a 50 day moving average of $4.04 and a 200 day moving average of $4.04. Presbia PLC has a 12-month low of $1.86 and a 12-month high of $5.88.

An institutional investor recently raised its position in Presbia PLC stock. FMR LLC lifted its position in Presbia PLC (NASDAQ:LENS) by 0.5% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,568,278 shares of the medical instruments supplier’s stock after purchasing an additional 13,375 shares during the quarter. FMR LLC owned about 15.15% of Presbia PLC worth $5,856,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 16.50% of the company’s stock.

Presbia PLC Company Profile

Presbia PLC is an ophthalmic device company. The Company develops and markets an optical lens implant for treating presbyopia, the age-related loss of the ability to focus on near objects. The Company’s segment is the restoration of clear vision caused by presbyopia. The Company prov

Presbia PLC (NASDAQ:LENS) – Analysts at Jefferies Group issued their Q1 2018 earnings per share estimates for Presbia PLC in a note issued to investors on Thursday. Jefferies Group analyst R. Denhoy anticipates that the medical instruments supplier will post earnings of ($0.24) per share for the quarter. Jefferies Group currently has a “Buy” rating and a $10.00 price target on the stock. Jefferies Group also issued estimates for Presbia PLC’s Q2 2018 earnings at ($0.26) EPS, Q3 2018 earnings at ($0.35) EPS, Q4 2018 earnings at ($0.39) EPS and FY2021 earnings at ($0.45) EPS.

TRADEMARK VIOLATION NOTICE: “Presbia PLC to Post Q1 2018 Earnings of ($0.24) Per Share, Jefferies Group Forecasts (LENS)” was first posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this news story can be viewed at https://ledgergazette.com/2017/10/09/presbia-plc-to-post-q1-2018-earnings-of-0-24-per-share-jefferies-group-forecasts-lens.html.

A number of other equities research analysts have also issued reports on the stock. ValuEngine raised shares of Presbia PLC from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st. Zacks Investment Research raised shares of Presbia PLC from a “sell” rating to a “hold” rating in a report on Tuesday, July 25th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $11.33.

Shares of Presbia PLC (LENS) opened at 5.1351 on Monday. The company’s market cap is $87.07 million. The stock has a 50 day moving average of $4.04 and a 200 day moving average of $4.04. Presbia PLC has a 12-month low of $1.86 and a 12-month high of $5.88.

An institutional investor recently raised its position in Presbia PLC stock. FMR LLC lifted its position in Presbia PLC (NASDAQ:LENS) by 0.5% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,568,278 shares of the medical instruments supplier’s stock after purchasing an additional 13,375 shares during the quarter. FMR LLC owned about 15.15% of Presbia PLC worth $5,856,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 16.50% of the company’s stock.

Presbia PLC Company Profile

Presbia PLC is an ophthalmic device company. The Company develops and markets an optical lens implant for treating presbyopia, the age-related loss of the ability to focus on near objects. The Company’s segment is the restoration of clear vision caused by presbyopia. The Company provides the refractive lens for patient surgeries and accessories for procedures performed exclusively outside the United States.

Earnings History and Estimates for Presbia PLC (NASDAQ:LENS)

Receive News & Ratings for Presbia PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Presbia PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply